Company Overview of Lithera, Inc.
Lithera, Inc. develops pharmaceutical and biomedical products that address medical and lifestyle indications in ophthalmology and aesthetic medicine. It offers LIPO-102, an injectable pharmaceutical product for local and selective fat reduction therapy. The company’s LIPO-102 is also used for the treatment of symptomatic exophthalmos associated with thyroid-related eye disease and the reduction of abdominal adiposity. Lithera, Inc. was founded in 2007 and is based in San Diego, California.
9191 Towne Centre Drive
San Diego, CA 92122
Founded in 2007
Key Executives for Lithera, Inc.
Vice President of Finance and Administration
Vice President of Pharmaceutical Development & Manufacturing
Compensation as of Fiscal Year 2014.
Lithera, Inc. Key Developments
Lithera, Inc. Presents at 13th Annual Needham Healthcare Conference, Apr-09-2014 08:40 AM
Mar 19 14
Lithera, Inc. Presents at 13th Annual Needham Healthcare Conference, Apr-09-2014 08:40 AM. Venue: The Westin Grand Central Hotel, New York, New York, United States. Speakers: George W. Mahaffey, Chief Executive Officer, President and Director.
Lithera, Inc. Presents at Cowen & Co. 34th Annual Health Care Conference, Mar-04-2014 10:00 AM
Feb 27 14
Lithera, Inc. Presents at Cowen & Co. 34th Annual Health Care Conference, Mar-04-2014 10:00 AM. Venue: Marriott Copley Place Hotel, Boston, Massachusetts, United States. Speakers: George W. Mahaffey, Chief Executive Officer, President and Director.
Lithera, Inc. Appoints Lincoln Krochmal as Chief Medical Officer
Nov 21 13
Lithera, Inc. announced the appointment of Lincoln Krochmal, M.D., as Chief Medical Officer. This appointment reflects the continued growth of Lithera as it prepares to enter late-stage clinical trials and to commercialize its lead product candidate, LIPO-202 (Salmeterol Xinafoate for Injection). Krochmal is a board-certified dermatologist and an authority on the development and commercialization of products for the dermatology and aesthetics markets. During his more than 30 year career, he played a pivotal role in the approval of 15 NDAs/ANDAs for new prescription topical dermatologicals including LacHydrin(R), Ultravate(R), Dovonex(R), Evoclin(R), Verdeso(R), Olux-E(R), Extina(R) and multiple consumer OTC products while with Unilever. Prior to Lithera, Dr. Krochmal was President and Chief Executive Officer of Excaliard Pharmaceuticals, an aesthetics company acquired by Pfizer, Inc., which developed novel treatments for the reduction of skin scarring.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|